Ventfort®
Division of patients by nosological forms, sex and age Table 1
Diagnosis Age Male Female Total
(years)
Control Primary Control Primary Control Primary
group group group group group group
Atherosclerosis of the arteries 52-71 9 11 6 9 15 20
Senile purpura 72-84 2 4 4 3 7 7
Total 11 15 10 12 22 27
RESEARCH METHODS
The patients’ complaints were assessed in dynamics. A general clinical examination of blood and urine
and a biochemical study of blood on the «REFLOTRON» apparatus (Boehringer Mannheim, Germany)
were carried out. To study homeostasis, we assessed the blood coagulogram, and the Hess test was
carried out.
RESEARCH RESULTS
We found that the use of VENTFORT® in patients with arterial atherosclerosis contributed to the
improvement of general well-being, especially in patients with cerebrovascular disorders.
As can be seen from Table 2, the use of VENTFORT® contributed to a significant decrease in the lev-
el of total cholesterol in the blood. There was also a tendency towards a reduction of the content of
very-low-density lipoproteins, which are the most atherogenic.
The majority of patients have seen an improvement in skin and hair conditions. A significant increase
in the strength of the capillary walls was observed in patients with senile purpura after the use of
VENTFORT®, as evidenced by the results of the Hess test. The incidence of bleeding spots decreased.
Influence of VENTFORT® on lipid metabolism indicators Table 2
Indicator Before treatment After treatment with After treatment with
general-purpose drugs Ventfort®
Total cholesterol, 8,6±0,4 7,2±0,5* 6,0±0,7*
(mmol/l)
Very low-density lipoproteins, 1,32±0,05 1,13±0,07 0,91±0,07
(mmol/l)
Triglycerides, (mmol/l) 4,7±0,5 4,3±0,6 4,1±0,6
* P <0.05 –reliable in comparison with the indicator before treatment.
An improvement in the skin condition and an increase in the strength of the walls of the capillaries
were observed in patients with senile purpura after the application of VENTFORT®, as evidenced by
the results of the Hess test. The incidence of bleeding spots decreased.
Thus, the results of this study indicate the therapeutic efficacy of VENTFORT® and the viability of its
use in the complex treatment of atherosclerosis and vascular pathology.
When using VENTFORT®, no side effects, complications, contraindications, or drug dependence were
observed.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.